The US Food and Drug Administration (FDA) last week approved a tuberculosis (TB) treatment regimen containing a new drug, pretomanid, offering a shorter, more effective course of treatment for highly drug-resistant strains of TB, the world’s leading cause of death by infectious disease. Pretomanid is only the third TB drug to be approved in over […] Continue reading ->
A new study suggests that the deadly drug-resistant fungus, Candida auris, may have adapted to warmer ambient temperatures caused by climate change, enabling it to survive in human body temperatures and infect humans with weakened immune systems, primarily in hospitals. The study, published in the journal of The American Society for Microbiology in July, posits […] Continue reading ->
NAIROBI – Neonatal sepsis is one of the leading causes of newborn deaths globally, and increasing pathogen resistance to available first-line treatments is a prime example of rising antimicrobial resistance. That is why the Global Antibiotic Research and Development Partnership (GARDP) – a non-profit research organisation that develops new or improved antibiotic treatments – is […] Continue reading ->
The Global Antibiotic Research & Development Partnership (GARDP) has announced its new “5 BY 25” strategy to mobilise global stakeholders to raise the €500 million needed to develop and deliver five new antibiotic treatments by 2025, to help tackle antimicrobial resistance (AMR). Drug-resistant infections already cause at least 700,000 deaths globally each year, and affect […] Continue reading ->
The World Health Organization (WHO) today launched a global AWaRe campaign, which aims to support national health systems to make more judicious use of lifesaving drugs so as to combat a worldwide trend of antimicrobial resistance (AMR) – including increased pathogen resistance to common antibiotics, antivirals and anti-fungal medications. However, WHO’s own 2018 Report on […] Continue reading ->
Nine months after a historic high-level UN meeting where countries pledged to end the global tuberculosis epidemic by 2030, a chronic lack of R&D financing jeopardises that ambitious goal, said expert panelists at a briefing on the TB R&D landscape last week in Geneva, hosted by South Africa’s Permanent Mission to the UN. While there […] Continue reading ->
After applauding the United States Congress for passing a bill that aims to strengthen preparedness against global disease threats, an R&D advocacy group is now calling on Congressional leaders to ensure there is actually money allocated to fund an expanded set of activities. Image Credits: PATH/Eric Becker. Continue reading ->
Deaths from infections resistant to common antibiotics, antivirals and anti-parasitic drugs could increase more than ten-fold to 10 million deaths annually by 2050, warns a ground-breaking United Nations report released today. Image Credits: WHO/Quinn Mattingly, UN. Continue reading ->
[CDDEP Press Release] In a new report, CDDEP researchers identify key barriers that prevent access to antibiotics in LMICs and provides potential solutions to address them. Antibiotic resistance is an emerging global public health threat spurred by the overuse and misuse of antibiotics. While “overuse” of antibiotics is widely accepted as a major health challenge, […] Continue reading ->
[GARDP Press Release] [Geneva/San Francisco/Brisbane/Saarbrücken – 11 April 2019] Multi-actor partnership tests natural products and compound libraries for antibacterial activity Discovery efforts will focus on World Health Organization’s (WHO) priority pathogens The Global Antibiotic Research and Development Partnership (GARDP) is partnering with Calibr, the Helmholtz Centre for Infection Research (HZI), in particular its location Helmholtz-Institute […] Continue reading ->